Macquarie Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Macquarie Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,300	Closed	-$18K	–	1881
2022 Q3	$18K	Hold	2,300	–	–	﹤0.01%	2229
2022 Q2	$16K	Hold	2,300	–	–	﹤0.01%	2360
2022 Q1	$35	Hold	2,300	–	–	﹤0.01%	2254
2021 Q4	$50K	Hold	2,300	–	–	﹤0.01%	2163
2021 Q3	$62K	Buy	+2,300	New	+$65.6K	﹤0.01%	2157

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Macquarie Group's FDMT Position: Q4 2022 in Review

Macquarie Group sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 2,300 shares — an estimated $18K sold.

Macquarie Group first reported a position in FDMT in Q3 2021 and held it in 5 quarters. The position peaked at $62K in Q3 2021. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

Macquarie Group reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 2,300 4D Molecular Therapeutics shares in Q4 2022, an estimated $18K.
Macquarie Group first reported a position in 4D Molecular Therapeutics in Q3 2021 and held it in 5 quarters.
Macquarie Group's 4D Molecular Therapeutics position peaked at $62K in Q3 2021.
96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.